Driver mutation VAF dropping within the first month of treatment is not what type I JAK2 inhibitors do — and that single early signal is what makes Ajax Therapeutics’ Phase 1 data worth scrutinizing before the full presentation hits the floor at EHA in Stockholm on June 13. The entire premise of AJ1-11095 rests on binding JAK2 in its type II inactive conformation rather than the type I active conformation targeted by ruxolitinib, pacritinib, and fedratinib. That structural distinction is not a minor refinement; it is the mechanistic argument for disease modification in a population that has already failed the standard of care.
The AJX-101 trial enrolls exclusively patients who have progressed on or are intolerant of a type I JAK inhibitor — meaning every person in this study has already exhausted the dominant treatment paradigm. Median overall survival after ruxolitinib failure runs roughly 14 months in the real-world data, so this is a population with a hard biological clock. The study covers all three myelofibrosis subtypes: primary MF, post-PV MF, and post-ET MF, with enrollment across both U.S. and European sites. An open-label Phase 1 design means the forthcoming oral presentation will center on safety and tolerability first, but the early VAF reduction signal Ajax has flagged publicly is the number that will drive the room’s attention — VAF changes this early suggest target engagement deep enough to affect the malignant clone, not just downstream cytokine suppression.
The competitive context tightens the stakes considerably. Constellation Pharmaceuticals’ pelabresib is advancing in combination with ruxolitinib for front-line MF, Imago BioSciences’ bomedemstat is in play, and navitoclax combinations have generated mutation clearance data that raised expectations for what disease modification actually looks like. Ajax is arriving at EHA claiming first-in-class status in a mechanism space where “disease modification” has been promised repeatedly and delivered inconsistently. The type II binding hypothesis is scientifically grounded — this is how imatinib works in BCR-ABL — but kinase-to-kinase translation is never automatic.
The single data point to track from the June 13 presentation is the depth and durability of VAF reduction correlated against spleen volume response rate; if those two signals are dissociated, the disease-modification thesis weakens substantially regardless of how clean the safety profile looks.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
